Lymphoma abstracts from the American Society of Hematology (ASH) 2015 convention in Orlando Florida
Click on any of the categories below to get a list of abstracts on that topic from the 2015 ASH convention. There is an outstanding amount of good information in these abstracts.
Better still, use the search box at the bottom. Fill in any terms of interest and find only abstracts from the 2015 convention that have those terms.
622. Non-Hodgkin Lymphoma: Biology, excluding Therapy: Bench to Bedside - Tools in Sight of Clinical Practice
622. Non-Hodgkin Lymphoma: Biology, excluding Therapy: Clinical Implications of Genomic Studies of B-cell Lymphomas
622. Non-Hodgkin Lymphoma: Biology, excluding Therapy: Deregulated Signaling Mechanisms in Lymphoid Malignancies
622. Non-Hodgkin Lymphoma: Biology, excluding Therapy: Genomic and Epigenetic Landscapes of Lymphoid Malignancies
622. Non-Hodgkin Lymphoma: Biology, excluding Therapy: New Targets In Aggressive Lymphoma
622. Non-Hodgkin Lymphoma: Biology, excluding Therapy: Refining The Molecular Roadmap In NHL
623. Lymphoma: Chemotherapy, excluding Pre-Clinical Models: Aggressive NHL - MCL, Burkitt, T-cell
623. Lymphoma: Chemotherapy, excluding Pre-Clinical Models: DLBCL - Beyond R-CHOP
623. Lymphoma: Chemotherapy, excluding Pre-Clinical Models: NHL - New Drugs
623. Lymphoma: Chemotherapy, excluding Pre-Clinical Models: Response Adapted Therapy and New Combinations in Hodgkin Lymphoma
624. Lymphoma: Therapy with Biologic Agents, excluding Pre-Clinical Models: Biologic Agents in B Cell Lymphoma
624. Lymphoma: Therapy with Biologic Agents, excluding Pre-Clinical Models: Biologic Agents in Hodgkin Lymphoma
624. Lymphoma: Therapy with Biologic Agents, excluding Pre-Clinical Models: Novel Immunotherapy Strategies in Lymphoma
701. Experimental Transplantation: Basic Biology, Engraftment, and Disease Activity
702. Experimental Transplantation: Immune Function, GVHD, and Graft-versus-Tumor Effects: Novel Approaches to Dampen GVHD
702. Experimental Transplantation: Immune Function, GVHD, and Graft-versus-Tumor Effects: Shifting the Balance Between GVH, GVT, and Post-transplant Immunity
703. Adoptive Immunotherapy: Clinical Studies
721. Clinical Allogeneic Transplantation: Conditioning Regimens, Engraftment and Acute Transplant Toxicities: Clinical and Biological Prognostic Markers, Donor Mobilization, Supportive Care
721. Clinical Allogeneic Transplantation: Conditioning Regimens, Engraftment and Acute Transplant Toxicities: Pediatric Studies and Interventional Studies for Viral Infections
721. Clinical Allogeneic Transplantation: Conditioning Regimens, Engraftment and Acute Transplant Toxicities: Regimens and Early Complications - Results of Prospective and Retrospective Studies
722. Clinical Allogeneic Transplantation: Acute and Chronic GVHD, Immune Reconstitution: Biological Studies
722. Clinical Allogeneic Transplantation: Acute and Chronic GVHD, Immune Reconstitution: Clinical Trials
723. Clinical Allogeneic and Autologous Transplantation: Late Complications and Approaches to Disease Recurrence: Late Complications and Immune Evasion
723. Clinical Allogeneic and Autologous Transplantation: Late Complications and Approaches to Disease Recurrence: Relapse
731. Clinical Autologous Transplantation: Results I
731. Clinical Autologous Transplantation: Results II
731. Clinical Autologous Transplantation: Results III
732. Clinical Allogeneic Transplantation: Results I
732. Clinical Allogeneic Transplantation: Results II
732. Clinical Allogeneic Transplantation: Results: Matched Related, Unrelated, and Alternative Donor Allograft Outcomes for Myeloid and Lymphoid Malignancies
732. Clinical Allogeneic Transplantation: Results: New Insights Into the Biology of Allogeneic Transplantation